News
ABUS
--
0.00%
--
8-K: Arbutus Biopharma Corp
(EDGAR Online via COMTEX) -- 0001447028 False 0001447028 2021-01-25 2021-01-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 13h ago
BRIEF-Arbutus Biopharma Expects Net Cash Burn To Range From $70 To $75 Million In 2021 And Therefore Cash Runway Extends To Mid-2022
reuters.com · 15h ago
Arbutus Announces 2021 Corporate Objectives and Provides Financial Update
GlobeNewswire · 15h ago
Arbutus Sets Out Clinical Objectives for 2021
MT Newswires · 18h ago
Global RNA-Based Therapeutics and Vaccines Market Driving Factors, 2025 Market Analysis, Investment Feasibility and Trends
Jan 25, 2021 (The Expresswire) -- Global “RNA-Based Therapeutics and Vaccines Market” is segmented by region, players, by Type, and by Application. Players,...
The Express Wire · 19h ago
RNA Therapy Market Outlook, Size, Share, Revenue, Regions & Forecast
Japan, Japan, Wed, 20 Jan 2021 07:27:16 / Comserve Inc. / -- RNA Therapy Market : Incredible Possibilities, Growth With Industry Study, Detailed Analysis and...
Comserve · 5d ago
Global RNAi Technology Market 2020 Industry Outlook, Key Players, Segmentation Analysis, Business Growth and Forecast to 2025
Jan 17, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has added a new report Global RNAi Technology Market 2020 by Company, Type and Application,...
CDN Newswire · 01/17 14:38
Technologies for Delivery of Proteins, Antibodies and Nucleic Acids Market 2021 to 2024 Production, Value (USD), Share by Region Like North America, Europe, China, Japan, Middle East & Africa, India, South 360 Market Updates
Jan 14, 2021 (The Expresswire) -- Global“Technologies for Delivery of Proteins, Antibodies and Nucleic AcidsMarket” Report 2021 - 2024 delivers the latest...
The Express Wire · 01/14 07:24
Global RNAi Technology Market 2020 Upcoming Trends, Latest Innovation, Advance Technology and Top Companies to 2025
Jan 13, 2021 (CDN Newswire via Comtex) -- The latest informative study entitled Global RNAi Technology Market 2020 by Company, Regions, Type and Application,...
CDN Newswire · 01/13 17:52
Global Antisense Therapy Market Size Study with COVID-19 Impact 2020 Research Strategies and Forecast to 2025
Jan 13, 2021 (CDN Newswire via Comtex) -- Global Antisense Therapy Market 2020 by Company, Type and Application, Forecast to 2025 published via...
CDN Newswire · 01/13 14:09
Global Antisense Therapy Market 2020 Competitive Dynamics, Growth Analysis, Segmentation and Worldwide Players Strategies up to 2025
Jan 13, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has added a new report Global Antisense Therapy Market 2020 by Company, Regions, Type and...
CDN Newswire · 01/13 13:26
Hepatitis B Treatment Market 2020: Company Profiles, Global Segments, Size, Landscape, Demand and Recent Trends by Forecast to 2023
Heraldkeepers · 01/12 03:18
Global Next-Generation Batteries Market Analysis, Size, Share, Growth, Trends and Forecast 2025
Jan 11, 2021 (Market Insight Reports) -- Selbyville, Delaware Metabolic Syndrome Market research now available at Market Study Report encompasses an...
Market Insight Reports · 01/11 19:38
Global RNAi for Therapeutic Market Outlook 2021: Market Trends, Segmentation, consumption by Regional data, Market Growth and Competitive Landscape
Jan 11, 2021 (The Expresswire) -- RNAi for Therapeutic Market provides detailed analysis of Market Overview, Drivers, Prospects, Potential Application. Also...
The Express Wire · 01/11 06:33
AY, ABUS, ACLS and FIXX among after-hours movers
Gainers: [[VIVO]] +6%. [[ABUS]] +4.6%. [[AY]] +4.2%. [[EBON]] +3.5%. [[TSE]] +3.4%.Losers: [[ACLS]] -14%. [[DOGZ]] -8.5%. [[HX]] -7.8%. [[FIXX]] -5.9%. [[JRJC]] -2.1%.
Seekingalpha · 01/08 22:43
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), tod...
GlobeNewswire · 01/04 13:00
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapi...
GlobeNewswire · 01/04 13:00
Are Investors Undervaluing Arbutus Biopharma Corporation (NASDAQ:ABUS) By 26%?
Simply Wall St. · 01/01 04:11
Thinking about buying stock in Vistagen Therapeutics, Adapthealth, PainReform, Arbutus Biopharma, or AIM ImmunoTech?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTGN, AHCO, PRFX, ABUS, and AIM.
PR Newswire - PRF · 12/18/2020 14:31
X, CLNY, MVIS and AIR among after-hours movers
Gainers: [[MREO]] +37.1%. [[BW]] +9.1%. [[ABUS]] +6.1%. [[CLNY]] +5.1%. [[MVIS]] +4.4%.Losers: [[SCPS]] -22.7%. [[SCHL]] -13%. [[SCS]] -7.3%. [[AIR]] -6.8%. [[X]] -5.1%.
Seekingalpha · 12/17/2020 22:44
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.
More